甲状腺自身免疫对甲状腺功能正常女性宫腔内人工授精后活产率的影响
这项回顾性队列研究纳入2010年1月1日至2014年12月31日在本生育中心启动首个IUI周期的3143例甲状腺功能正常患者,比较抗TPO阳性组与阴性组的活产率。结果显示两组活产、妊娠及流产率均无显著差异,TSH≥2.5 mIU/l与<2.5 mIU/l亚组间亦无显著差异。
要点
- 甲状腺自身免疫不影响甲状腺功能正常女性IUI后的活产率。
- 抗TPO阳性与阴性组活产率OR 1.04(95%CI 0.63;1.69),无显著差异。
- TSH≥2.5与<2.5 mIU/l亚组活产率OR 1.05(95%CI 0.76;1.47),无显著差异。
核心结论
- 甲状腺自身免疫不影响甲状腺功能正常女性IUI治疗后的妊娠结局。
- 未能证实TSH水平高于2.5 mIU/l对活产率有负面影响。
- 作者认为在TSH 2.5–4 mIU/l时提倡左甲状腺素治疗需谨慎,并需在前瞻性队列研究中进一步分析。
研究设计与样本
- 回顾性队列研究,采用抗TPO阳性与抗TPO阴性两组设计。
- 纳入2010年1月1日至2014年12月31日在本生育中心启动首个IUI周期的患者,随访结局至2015年12月31日。
- 排除临床甲状腺功能异常(TSH<0.01 mIU/l或TSH>5 mIU/l)及接受左甲状腺素或抗甲状腺药物治疗者后,最终纳入3143例患者。
主要发现
- 抗TPO阳性组与抗TPO阴性组活产率OR 1.04(95%CI 0.63;1.69),无显著差异。
- 抗TPO阳性组与抗TPO阴性组妊娠率OR 0.98(95%CI 0.62;1.55),无显著差异。
- 抗TPO阳性组与抗TPO阴性组流产率OR 0.74(95%CI 0.23;2.39),无显著差异。
- TSH≥2.5 mIU/l组与TSH<2.5 mIU/l组活产率OR 1.05(95%CI 0.76;1.47),无显著差异。
- TSH≥2.5 mIU/l组与TSH<2.5 mIU/l组妊娠率OR 1.04(95%CI 0.77;1.41),流产率OR 0.95(95%CI 0.47;1.94),均无显著差异。
关键数值与推荐
- 主要终点为妊娠25周后的活产分娩。
- 次要终点按孕前TSH上限阈值<2.5与<5.0 mIU/l比较活产率差异。
- 分析TSH、fT4、抗TPO状态、年龄、吸烟、BMI、产次、卵巢储备(AMH与FSH)、IUI指征及IUI刺激对活产率的影响。
临床怎么用
- 作者认为在TSH 2.5–4 mIU/l时提倡左甲状腺素治疗需谨慎,并需在前瞻性队列研究中进一步分析。
局限性
- 本研究把握度针对主要目标活产率设计。
- 缺乏甲状腺激素的地区特异性参考范围。
- 缺乏辅助生殖技术期间及后续妊娠期间TSH值的随访。
- 甲状腺评估与刺激开始之间相隔5个月。
- 研究所在地区为轻度碘缺乏地区,数据外推至碘背景不同的地区需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does thyroid autoimmunity (TAI) predict live birth rate in euthyroid women after one treatment cycle in IUI patients? SUMMARY ANSWER: TAI as such does not influence pregnancy outcome after IUI treatment. WHAT IS KNOWN ALREADY: The role of TAI on pregnancy outcome in the case of IVF/ICSI is largely debated in the literature. This is the first study to address this issue in the case of IUI. STUDY DESIGN, SIZE, DURATION: This was a retrospective cohort study. A two-armed study design was performed: patients anti-thyroid peroxidase (TPO)+ and patients anti-TPO-. All patients who started their first IUI cycle in our fertility center between 1 January 2010 and 31 December 2014 were included. After exclusion of those patients with or being treated for thyroid dysfunction, 3143 patients were finally included in the study. PARTICIPANTS/MATERIALS, SETTING, METHODS: After approval by the institutional review board we retrospectively included all patients who started their first IUI cycle in our center between 1 January 2010 and 31 December 2014 with follow-up of outcome until 31 December 2015. Patients with clinical thyroid dysfunction were excluded (thyroid-stimulating hormone (TSH) <0.01 mIU/l; TSH >5 mIU/l) as were patients under treatment with levothyroxine or anti-thyroid drugs. These patients were then divided into two main groups: patients anti-TPO+ and patients anti-TPO- (= control group). Live birth delivery after 25 weeks of gestation was taken as the primary endpoint of our study. As a secondary endpoint, we evaluated differences in live birth delivery after IUI according to different upper limits of preconception TSH thresholds (<2.5 and <5.0 mIU/l). Furthermore, the influence of thyroid function (TSH, free thyroxine (fT4)), anti-TPO status, age, smoking, BMI, parity, ovarian reserve (anti-mullerian hormone (AMH) and FSH), IUI indication and IUI stimulation on live birth rate was analyzed. MAIN RESULTS AND THE ROLE OF CHANCE: Between-group comparison did not show any significant difference between the anti-TPO+ and anti-TPO- group with respect to live birth delivery-, pregnancy- or miscarriage rate with odds ratio at 1.04 (95% CI: 0.63; 1.69), 0.98 (95% CI: 0.62; 1.55) and 0.74 (95% CI: 0.23; 2.39), respectively. In addition, there were no significant differences in live birth delivery-, pregnancy- or miscarriage rate when comparing subgroups according to TSH level (TSH ≥2.5 mIU/l vs. TSH <2.5 mIU/l) with an odds ratio at 1.05 (95% CI: 0.76; 1.47), 1.04 (95% CI: 0.77; 1.41) and 0.95 (95% CI: 0.47; 1.94), respectively. LIMITATIONS, REASONS FOR CAUTION: This study was powered for the primary aim, live birth rate. The limitations of this study are the absence of region-specific reference ranges for thyroid hormones and the absence of follow-up of TSH values during ART and subsequent pregnancy. Moreover, there was a time difference of 5 months between thyroid assessment and the start of stimulation. The area where the study was conducted corresponds to a mild iodine deficient area and data should be translated with caution to areas with different iodine backgrounds. WIDER IMPLICATIONS OF THE FINDINGS: Our findings indicate comparable pregnancy-, abortion- and delivery rates in women with and without TAI undergoing IUI. Moreover, we were unable to confirm a negative effect of TSH level above 2.5 mIU/l on live birth delivery rate. We therefore believe that advocating Levothyroxine treatment at TSH levels between 2.5 and 4 mIU/l needs to be considered with caution and requires further analysis in a prospective cohort study. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used for this study. No conflicts of interest are declared.
引用
- Unuane D, Velkeniers B, Bravenboer B, et al. Impact of thyroid autoimmunity in euthyroid women on live birth rate after IUI. Hum Reprod. 2017. PMID: 28333271. doi:10.1093/humrep/dex033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。